[go: up one dir, main page]

WO2002010369A1 - Tumor antigen - Google Patents

Tumor antigen Download PDF

Info

Publication number
WO2002010369A1
WO2002010369A1 PCT/JP2001/006526 JP0106526W WO0210369A1 WO 2002010369 A1 WO2002010369 A1 WO 2002010369A1 JP 0106526 W JP0106526 W JP 0106526W WO 0210369 A1 WO0210369 A1 WO 0210369A1
Authority
WO
WIPO (PCT)
Prior art keywords
tumor antigen
peptide
polynucleotide
tumor
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2001/006526
Other languages
English (en)
French (fr)
Inventor
Kyogo Itoh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP01984425A priority Critical patent/EP1306431B1/en
Priority to CA2417570A priority patent/CA2417570C/en
Priority to AU2002227498A priority patent/AU2002227498A1/en
Priority to JP2002516288A priority patent/JP4900884B2/ja
Priority to DE60133287T priority patent/DE60133287T2/de
Priority to ES01984425T priority patent/ES2304398T3/es
Application filed by Individual filed Critical Individual
Publication of WO2002010369A1 publication Critical patent/WO2002010369A1/ja
Priority to US10/353,929 priority patent/US7148326B2/en
Anticipated expiration legal-status Critical
Priority to US11/543,066 priority patent/US7408037B2/en
Priority to US11/543,065 priority patent/US7524930B2/en
Priority to US11/543,087 priority patent/US7427660B2/en
Priority to US11/543,088 priority patent/US7404270B2/en
Priority to US11/543,089 priority patent/US7432354B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/54—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/JP2001/006526 2000-07-31 2001-07-30 Tumor antigen Ceased WO2002010369A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
EP01984425A EP1306431B1 (en) 2000-07-31 2001-07-30 Tumor antigen
CA2417570A CA2417570C (en) 2000-07-31 2001-07-30 Tumor-specific t cell activation by peptide antigens
AU2002227498A AU2002227498A1 (en) 2000-07-31 2001-07-30 Tumor antigen
JP2002516288A JP4900884B2 (ja) 2000-07-31 2001-07-30 腫瘍抗原
DE60133287T DE60133287T2 (de) 2000-07-31 2001-07-30 Tumorantigen
ES01984425T ES2304398T3 (es) 2000-07-31 2001-07-30 Antigeno de tumores.
US10/353,929 US7148326B2 (en) 2000-07-31 2003-01-30 Tumor antigen
US11/543,066 US7408037B2 (en) 2000-07-31 2006-10-05 Tumor antigen
US11/543,089 US7432354B2 (en) 2000-07-31 2006-10-05 Tumor antigen
US11/543,088 US7404270B2 (en) 2000-07-31 2006-10-05 Tumor antigen
US11/543,065 US7524930B2 (en) 2000-07-31 2006-10-05 Tumor antigen
US11/543,087 US7427660B2 (en) 2000-07-31 2006-10-05 Tumor antigen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000-231814 2000-07-31
JP2000231814 2000-07-31

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/353,929 Continuation-In-Part US7148326B2 (en) 2000-07-31 2003-01-30 Tumor antigen

Publications (1)

Publication Number Publication Date
WO2002010369A1 true WO2002010369A1 (en) 2002-02-07

Family

ID=18724591

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/006526 Ceased WO2002010369A1 (en) 2000-07-31 2001-07-30 Tumor antigen

Country Status (9)

Country Link
US (6) US7148326B2 (ja)
EP (1) EP1306431B1 (ja)
JP (1) JP4900884B2 (ja)
AT (1) ATE389668T1 (ja)
AU (1) AU2002227498A1 (ja)
CA (1) CA2417570C (ja)
DE (1) DE60133287T2 (ja)
ES (1) ES2304398T3 (ja)
WO (1) WO2002010369A1 (ja)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005073374A1 (ja) * 2004-01-29 2005-08-11 Dainippon Sumitomo Pharma Co., Ltd. 新規腫瘍抗原蛋白質及びその利用
JP2011522527A (ja) * 2008-05-20 2011-08-04 インスティティ・パスツール プラス一本鎖ｒｎａウイルスへの感染の予防又は治療のためのヒト大型２’，５’−オリゴアデニル酸合成酵素ｏａｓ３
WO2011108628A1 (ja) * 2010-03-03 2011-09-09 東レ株式会社 胃癌検出用マーカー及び胃癌検出方法
KR101294514B1 (ko) * 2007-09-18 2013-08-12 가부시키가이샤 그린 펩티드 Ｃｔｌ 유도제 조성물
WO2014136814A1 (ja) 2013-03-08 2014-09-12 大鵬薬品工業株式会社 新規ｃｔｌエピトープ５連結ペプチド
WO2015060235A1 (ja) * 2013-10-21 2015-04-30 大鵬薬品工業株式会社 新規ｃｔｌエピトープ４連結ペプチド
WO2020004622A1 (ja) 2018-06-29 2020-01-02 大鵬薬品工業株式会社 抗腫瘍剤及びその評価方法
WO2021132550A1 (ja) 2019-12-26 2021-07-01 大鵬薬品工業株式会社 術後補助療法剤
JP2024096712A (ja) * 2016-05-13 2024-07-17 バイオエヌテック エスエー 免疫療法に対するタンパク質又はタンパク質のフラグメントの有用性を予測するための方法

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2192407A3 (en) * 2001-09-18 2011-04-27 Green Peptide Co., Ltd. Method of detecting cellular immunity and application thereof to drugs
US20080200088A1 (en) * 2007-02-21 2008-08-21 Chong Pyung An Method for reducing interference fringes in a display device
EA201171259A1 (ru) 2009-04-22 2012-05-30 Мерк Патент Гмбх Антительные гибридные белки с модифицированными сайтами связывания fcrn
WO2011000551A1 (en) 2009-07-02 2011-01-06 Ith Immune Therapy Holdings Ab Exosome based treatment of cancer
JP5897035B2 (ja) 2010-12-14 2016-03-30 ユニバーシティ オブ メリーランド，ボルチモア 汎用の抗タグキメラ抗原受容体発現ｔ細胞及びがんを治療する方法
CA2847109A1 (en) * 2011-08-29 2013-03-07 Toray Industries, Inc. Marker for detecting colorectal cancer or esophageal cancer and method for examining such cancer
PL2895600T3 (pl) * 2012-09-11 2020-10-05 Oncotherapy Science, Inc. Peptydy UBE2T i szczepionki je zawierające
ES2776698T3 (es) 2012-12-20 2020-07-31 Purdue Research Foundation Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer
GB201522667D0 (en) * 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
SG10202111399YA (en) 2015-12-22 2021-11-29 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201604458D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
WO2017177149A2 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
WO2018148224A1 (en) 2017-02-07 2018-08-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
CN110582288B (zh) 2017-02-28 2024-09-20 恩多塞特公司 用于car t细胞疗法的组合物和方法
WO2019004415A1 (ja) 2017-06-30 2019-01-03 国立大学法人大阪大学 末梢血ｔ細胞の腫瘍細胞傷害活性を指標とする腫瘍免疫療法の効果予測方法
US11446317B2 (en) 2017-10-26 2022-09-20 Otsuka Pharmaceutical Co., Ltd. Inositol phosphate-containing composition
WO2019144091A1 (en) 2018-01-22 2019-07-25 Endocyte, Inc. Methods of use for car t cells
WO2019156795A1 (en) 2018-02-06 2019-08-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
JP7568224B2 (ja) 2018-02-23 2024-10-16 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための配列決定法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874231A (en) * 1994-08-22 1999-02-23 Mcgill University Methods of screening for non-hormone compounds which effect modulation of polypeptide translation
US5936078A (en) 1995-12-12 1999-08-10 Kyowa Hakko Kogyo Co., Ltd. DNA and protein for the diagnosis and treatment of Alzheimer's disease
WO1997021807A1 (fr) * 1995-12-12 1997-06-19 Kyowa Hakko Kogyo Co., Ltd. Nouveaux adn, nouveaux polypeptides et nouveaux anticorps
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
JP2000189168A (ja) * 1998-12-28 2000-07-11 Hiroshi Handa 新規転写伸長抑制因子
AU6321400A (en) * 1999-08-17 2001-03-13 Protegene Inc. Human proteins having hydrophobic domains and dnas encoding these proteins

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
AKIRA YAMADA ET AL.: "Study of HLA class I restriction and the directed antigens of cytotoxic T lymphocytes at the tumor sites of ovarian cancer", CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 48, May 1999 (1999-05-01) - June 1999 (1999-06-01), pages 147 - 152, XP002948572 *
DAMU YANG ET AL.: "Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients", CANCER RESEARCH, vol. 59, August 1999 (1999-08-01), pages 4056 - 4063, XP002948567 *
KYOGO ITOH ET AL.: "A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumor-specific CTLs", J. IMMUNOL., vol. 163, 1999, pages 4994 - 5004, XP002948569 *
MASAAKI ITO ET AL.: "Molecular basis of T cell-mediated recognition of pancreatic cancer cells", CANCER RESEARCH, vol. 61, March 2001 (2001-03-01), pages 2038 - 2046, XP002948565 *
MEGUMI KIKUCHI ET AL.: "Identification of a sart-1-derived peptide capable of inducing HLA-A24-restricted and tumor specific cytotoxic T lymphocytes", INT. J. CANCER, vol. 81, 1999, pages 459 - 466, XP002948568 *
PEIPER MATTHIAS ET AL.: "Pancreatic cancer associated ascites-derived CTL recognize a nine-amino-acid peptide GP2 derived from HER2/neu", ANTICANCER RESEARCH, vol. 19, July 1999 (1999-07-01) - August 1999 (1999-08-01), pages 2471 - 2476, XP002948573 *
SHIGEKI SHICHIJO ET AL.: "A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes", J. EXP. MED., vol. 187, no. 3, 1998, pages 277 - 288, XP002948570 *
TETSUYA NAKATSURA ET AL.: "Gene cloning of immunogenic antigens overexpressed in pancreatic cancer", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 281, 2001, pages 936 - 944, XP002948571 *
UGUR SAHIN ET AL.: "Human neoplasms elicit multiple specific immune responses in the autologous host", PROC. NATL. ACAD. SCI. USA, vol. 92, December 1995 (1995-12-01), pages 11810 - 11813, XP002948566 *

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005073374A1 (ja) * 2004-01-29 2005-08-11 Dainippon Sumitomo Pharma Co., Ltd. 新規腫瘍抗原蛋白質及びその利用
US9102715B2 (en) 2007-09-18 2015-08-11 Green Peptide Co., Ltd. CTL inducer composition
KR101512885B1 (ko) * 2007-09-18 2015-04-16 가부시키가이샤 그린 펩티드 Ｃｔｌ 유도제 조성물
KR101294514B1 (ko) * 2007-09-18 2013-08-12 가부시키가이샤 그린 펩티드 Ｃｔｌ 유도제 조성물
JP5568309B2 (ja) * 2007-09-18 2014-08-06 株式会社グリーンペプタイド Ｃｔｌ誘導剤組成物
EP3494981A1 (en) 2007-09-18 2019-06-12 BrightPath Biotherapeutics Co., Ltd. Ctl inducer composition
EP2801367A1 (en) 2007-09-18 2014-11-12 Green Peptide Co., Ltd. CTL inducer composition
KR101479455B1 (ko) * 2007-09-18 2015-01-05 가부시키가이샤 그린 펩티드 Ｃｔｌ 유도제 조성물
KR101547788B1 (ko) 2007-09-18 2015-08-26 가부시키가이샤 그린 펩티드 Ｃｔｌ 유도제 조성물
US9642900B2 (en) 2007-09-18 2017-05-09 Green Peptide Co., Ltd. CTL inducer composition
EP3156061A1 (en) 2007-09-18 2017-04-19 Green Peptide Co., Ltd. Ctl inducer composition
JP2011522527A (ja) * 2008-05-20 2011-08-04 インスティティ・パスツール プラス一本鎖ｒｎａウイルスへの感染の予防又は治療のためのヒト大型２’，５’−オリゴアデニル酸合成酵素ｏａｓ３
US9081013B2 (en) 2010-03-03 2015-07-14 Toray Industries, Inc. Marker for detecting gastric cancer and method for detecting gastric cancer
JP5670422B2 (ja) * 2010-03-03 2015-02-18 東レ株式会社 胃癌検出用マーカー及び胃癌検出方法
WO2011108628A1 (ja) * 2010-03-03 2011-09-09 東レ株式会社 胃癌検出用マーカー及び胃癌検出方法
US9701729B2 (en) 2013-03-08 2017-07-11 Taiho Pharmaceutical Co., Ltd. Peptide having 5 linked CTL epitopes
WO2014136814A1 (ja) 2013-03-08 2014-09-12 大鵬薬品工業株式会社 新規ｃｔｌエピトープ５連結ペプチド
AU2014337643B2 (en) * 2013-10-21 2017-07-13 Taiho Pharmaceutical Co., Ltd. Novel four-CTL epitope-joined peptide
WO2015060235A1 (ja) * 2013-10-21 2015-04-30 大鵬薬品工業株式会社 新規ｃｔｌエピトープ４連結ペプチド
US10137183B2 (en) 2013-10-21 2018-11-27 Taiho Pharmaceutical Co., Ltd. Peptide compositions having 4 linked CTL epitopes and uses thereof
JP2024096712A (ja) * 2016-05-13 2024-07-17 バイオエヌテック エスエー 免疫療法に対するタンパク質又はタンパク質のフラグメントの有用性を予測するための方法
WO2020004622A1 (ja) 2018-06-29 2020-01-02 大鵬薬品工業株式会社 抗腫瘍剤及びその評価方法
US12251447B2 (en) 2018-06-29 2025-03-18 Taiho Pharmaceutical Co., Ltd. Combined formulation comprising four linked cytotoxic T lymphocyte (CTL) epitopes and a PD-1 pathway inhibitor and methods of use thereof to treat cancer
WO2021132550A1 (ja) 2019-12-26 2021-07-01 大鵬薬品工業株式会社 術後補助療法剤

Also Published As

Publication number Publication date
US20070031431A1 (en) 2007-02-08
AU2002227498A1 (en) 2002-02-13
EP1306431A1 (en) 2003-05-02
DE60133287D1 (de) 2008-04-30
EP1306431B1 (en) 2008-03-19
US7524930B2 (en) 2009-04-28
ES2304398T3 (es) 2008-10-16
CA2417570C (en) 2010-12-07
US7427660B2 (en) 2008-09-23
JP4900884B2 (ja) 2012-03-21
CA2417570A1 (en) 2003-01-31
US20070031432A1 (en) 2007-02-08
US20070031433A1 (en) 2007-02-08
US20070071767A1 (en) 2007-03-29
EP1306431A4 (en) 2004-08-18
US7148326B2 (en) 2006-12-12
ATE389668T1 (de) 2008-04-15
US20070066804A1 (en) 2007-03-22
DE60133287T2 (de) 2009-03-26
US20030175288A1 (en) 2003-09-18
US7404270B2 (en) 2008-07-29
US7432354B2 (en) 2008-10-07
US7408037B2 (en) 2008-08-05

Similar Documents

Publication Publication Date Title
WO2002010369A1 (en) Tumor antigen
WO2001075067A8 (en) Novel nucleic acids and polypeptides
WO2001057188A3 (en) Novel nucleic acids and polypeptides
WO2001057190A3 (en) Novel nucleic acids and polypeptides
WO2002022660A3 (en) Novel nucleic acids and polypeptides
WO2001066689A3 (en) Novel nucleic acids and polypeptides
WO2002031111A3 (en) Novel nucleic acids and polypeptides
WO2001053312A8 (en) Novel nucleic acids and polypeptides
WO2001053455A3 (en) Novel nucleic acids and polypeptides
WO2001088088A3 (en) Novel nucleic acids and polypeptides
WO2002059260A3 (en) Nucleic acids and polypeptides
WO1998038212A3 (en) Chimeric polypeptides containing chemokine domains
WO2003054152A3 (en) Novel nucleic acids and polypeptides
WO2002070539A3 (en) Novel nucleic acids and polypeptides
WO2003023013A3 (en) Novel nucleic acids and polypeptides
WO2002081731A3 (en) Novel nucleic acids and polypeptides
EP1092774A3 (en) Borrelia burgdorferi antigen OspA, gene encoding it and uses thereof
WO2003029271A3 (en) Novel nucleic acids and polypeptides
WO2002018424A3 (en) Nucleic acids and polypeptides
WO2001079449A3 (en) Novel nucleic acids and polypeptides
MXPA00003885A (es) Quimiocinas con modificiaciones de la terminacion amino.
CA2381348A1 (en) Lck-derived peptides activating ctls
WO2002044340A3 (en) Novel nucleic acids and polypeptides
EP1619207A3 (en) HLA-A2.1 binding peptides derived from HCV and their uses
WO2001053453A8 (en) Novel bone marrow nucleic acids and polypeptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001984425

Country of ref document: EP

Ref document number: 10353929

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2417570

Country of ref document: CA

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2001984425

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2001984425

Country of ref document: EP